Ghent University Hospital
Ghent, East Flanders, 9000, Belgium
NCT Number: NCT06796530
Medium-chain acyl-CoA dehydrogenase deficiency (MCADD) is a rare genetic disorder affecting the body's ability to break down certain fats (β-oxidation) for energy, leading to symptoms like hypoketotic hypoglycaemia, jaundice, cardiomyopathy and seizures. responsible for the dehydrogenation step of fatty acids with chain lengths between 6 and 12 carbons as they undergo beta-oxidation in the mitochondria. Deficiency in MCAD can result in energy deficiency, the accumulation of acylcarnitine's and low serum carnitine concentrations.
The primary objective of the pilot study is to analyse the effects of high-intensity exercise (cardiopulmonary exercise testing (CPET) & high intensity circuit exercises ) on metabolic parameters and safety. This research is a pilot study comparing four patients with MCADD to four control subjects with the same characteristics. Blood samples are collected for analysis of substrate utilization.
Looking for future studies?
Notify Me8 year–17 year
All sexes
Interventional
Not applicable
Ghent, East Flanders, 9000, Belgium
The primary objective of the study is to analyse the effects of high-intensity exercise (CPET & high intensity circuit exercises) on metabolic parameters and safety. Since exercise is tested approximately two hours after a meal, we expect few symptoms, as fat metabolism is only minimally engaged at this intensity. Of interest could be the recovery from exercise, as fat metabolism is presumably activated during this phase.
Each MCADD-patient will attend two experimental visits. On the day of the first visit, the patient will arrive at UZ Gent after 1.5-hours following the meal. After 30 minutes, they will perform a cardiopulmonary exercise test (CPET) on a cycle ergometer. The standard CPET protocol that will be used is as follows: first, three minutes of cycling at a constant load (body weight (kg) / 2) in Watts), followed by a maximal exercise test (Ramp protocol: (body weight (kg) / 4) in Watts per minute). During the cycling test, gas exchange (spirometry) is measured, and an ECG is taken. If no symptoms are observed, the patient may return home. On the second test day, two hours before the test, a breakfast will be consumed. 1.5-hours following the meal, the patient will arrive at UZ Gent, where a heart monitor will be placed, and an intravenous line will be inserted. Following this, the patient will undergo a high-intensity exercise circuit. Blood samples will be taken before and after the exercise at various intervals: immediately, after 30 minutes, 1 hour, and 1.5-hours. Also, RER will be determined at each timepoint using indirect calorimetry. If no symptoms appear, the patient may return home. The patient will report symptoms for the 48 hours following the test. In the blood samples, measures of substrate utilization will be monitored: Glucose, lactate, acylcarnitine levels, free fatty acids (FFA). Also a marker of muscle damage will be assessed (creatine kinase). Additional measures include: anthropometric measurements, including weight and height, physical activity through the children physical activity questionnaire).
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants undergo a CPET on a stationary bike, measuring gas exchange, ECG, and other parameters. The protocol includes 3 minutes of cycling at a constant load (body weight/2 in Watts), followed by a maximal effort test with an incremental load (Ramp protocol body weight (kg) / 4 in Watts per minute).
The patients will undergo a 10-minute warm-up, followed by ~30 high intensity exercise circuit.
Time frame: From start of exercise until 1.5 hours post-exercise.
Analysis of glucose in blood samples taken before, immediately after, and at intervals (30 minutes, 1 hour, and 1.5 hours) following high-intensity exercise.
Time frame: During CPET (approximately 30 minutes).
Measurement of maximal oxygen uptake during the cardiopulmonary exercise test (CPET) on a stationary bike.
Time frame: During and up to 48 hours post-exercise.
Monitoring and recording of any symptoms, adverse events, or complications during exercise and the following 48 hours
Time frame: From the end of the exercise circuit until 1.5 hours post-exercise.
Monitoring of acylcarnitines before and after high intensity exercise
Time frame: From the end of the exercise circuit until 1.5 hours post-exercise.
Assessment of serum creatine kinase (CK) levels before and after exercise
Time frame: From the end of the exercise circuit until 1.5 hours post-exercise.
Assessment of lactate levels before and after exercise
Time frame: From the end of the exercise circuit until 1.5 hours post high intensity exercise.
Monitoring of substrate utilization (including fat metabolism) through measurement of RER.
University Hospital, Ghent
Other
Medium-Chain Acyl-Coa Dehydrogenase Deficiency (MCADD) and Exercise
Acronym: MCADD-EX
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05687474
3-Hydroxy 3-Methyl Glutaric Aciduria, 3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency
Liège, Wallonia, Belgium
View Trial DetailsNCT02517307
Carnitine Palmitoyltransferase II Deficiency, Late-Onset, Carnitine Palmitoyltransferase II Deficiency, Myopathic
Portland, Oregon, United States
View Trial DetailsNCT01881984
Medium chain acyl CoA dehydrogenase deficiency, Medium-chain Acyl-CoA Dehydrogenase (MCAD) Deficiency
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT03655223
17 Alpha-Hydroxylase Deficiency, 3-Hydroxy-3-Methylglutaric Aciduria
Research Triangle Park, North Carolina, United States
View Trial Details